RPG Life Sciences Merger & Restructuring
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences for Rs. 135 Crore via a slump sale.